Blood Disorder Treatments

Publication Date	January 2007
Publisher	BCC Research
Product Type	Report
Pages	136
ISBN Number	not applicable
Product Code	BCC00179

Buy this product or for assistance call +44 20 7060 7474

PDF £2,960.00$4852 | €3452

PRINT £2,960.00$4852 | €3452

FAX Order above formats by FAX

Summary

This BCC report details the Market for Blood Disorder Treatments. The market is rapidly growing due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnosis. Emphasis has been placed on early detection and treatment of disorders. There are issues surrounding this market that are currently in the news that will ultimately shape this market for the future. An assessment of this market is presented to ensure that participants in the market do not get caught off guard, not having time to prepare for the future developments.

The objectives of the study are to heighten the awareness of blood disorders, their consequences and their treatments. The study analyzes pharmaceutical entities that are currently on the market and new products that are on the horizon.

Scope of study

This report contains:

Descriptions of various types of blood disorder treatments for anemia, hemophilia, neutropenia and thrombosis
The current market status of blood disorder treatments, trends and forecasts for growth over the next 5 years
Discussion of new technologies with a thorough patent analysis
Analysis of the major overhaul of the U.S. Food and Drug Administration's approval process for blood disorder treatments
Profiles of major players in the blood disorder treatment market.

Report Highlights

The global market for blood disorder treatments increased from $34.8 billion in 2006 to an estimated $36.7 billion by the end of 2007. It should reach nearly $44.0 billion by 2012, a compound annual growth rate (cagr) of 3.9%.
Anemia, hemophilia, neutropenia and thrombosis treatments are all slated for growth due to advances in diagnostics and drug design.
The thrombosis treatment segment accounts for the largest portion of revenues and is expected to be worth $16.4 billion by 2012.

Content

Chapter 1 - Executive Summary
- Executive Summary
- Summary Table: Market Size of Worldwide Blood Disorder Treatments by Revenue at Manufacturers' Sales Levels, through 2012 ($ Millions)
- Summary Figure: Market Size of Blood Disorder Treatments by Revenue at Manufacturers' Sales Levels, 2005-2012 ($ Millions)
Chapter 2 - Industry Overview
- Structure and Function of The Hematological System
  - Bone Marrow
  - Blood Cells
    - Red Blood Cells
    - White Blood Cells
    - Platelets
  - Spleen
  - Lymph System
  - Liver
  - Normal Clotting Mechanisms
- Effects of Aging on The Hematologic System
- Blood-Related Medical Conditions
  - Anemia
    - Anemia Caused by Decreased Erythrocyte Production
    - Iron Deficiency Anemia
    - Thalassemia
    - Megaloblastic Anemia
    - Vitamin B12 Deficiency
    - Anemia of Chronic Disease
    - Aplastic Anemia
    - Anemia Caused by Blood Loss
    - Anemia Caused by Increased Erythrocyte Destruction
    - Sickle Cell Disease
    - Glucose-6-Phosphate Dehydrogenase Deficiency
    - Acquired Hemolytic Anemia
    - Polycythemia
  - Hemophilia
  - Neutropenia
  - Thrombocytopenia
  - Thrombosis
    - Thromboembolus
    - Deep Vein Thrombosis
- Demographics and Statistics
  - Licensing Disputes
  - Rebate Issues
  - Fda Restrictions on Anemia Drugs
  - Telemedicine for Hemophilia
  - Hemophilia and Joint Damage
  - Education
  - Cost
  - Pharmaceutical Landscape Changes
    - The Impact of Biotechnology
  - Biogeneric Impact
  - Sedentary Lifestyles and Dvt
  - Medicare and The Elderly
  - Airline Travel Issues
  - Pharmaceutical Rebate Issues
- Product Segments by Type
  - Anemia Treatments
    - Aranesp/Nespo (Darbepoetin Alfa)
    - Procrit/Eprex (Epoetin Alfa)
    - Epogen (Epoetin Alfa)
    - NeoRecormon/Epogin (Epoetin Beta)
    - Anabolic Steroids
    - Cyanocobalamin and Combinations
    - Erythropoiesis Stimulants
    - Folic Acid and Derivatives
    - Iron and Derivatives
  - Hemophilia Treatments
    - Recombinants Group (BAXTER)
    - Kogenate
    - NovoSeven
    - Antihemophilic Factor
    - Anti-Inhibitor Coagulant Complex
    - Factor Ix Complex
  - Neutropenia Treatments
    - Neulasta/ Neupopeg (PEGFILGRASTIM)
    - Neupogen/ Granulokine (FILGRASTIM)
    - Granulocyte Colony Stimulating Factor
    - Granulocyte Macrophage Colony Stimulating Factor
  - Thrombosis Treatments
    - Lovenox (Enoxaparin Sodium)
    - Plavix (Clopidogrel Bisulfate)
    - Anticoagulants
    - Antiplatelet Agents
    - Antithrombin Iii Agents
    - Thrombin Inhibitors
    - Thrombolytic Agents
- New Approvals
Chapter 3 - Market Size and Growth
- Blood Disorder Treatment Market by Geography
- Blood Disorder Treatment Markets by Segment
  - Anemia Treatments Market
  - Hemophilia Treatments Market
  - Neutropenia Treatments Market
  - Thrombosis Treatments
Chapter 4 - Research and Development
- Treatments Awaiting Approval/Phase Trials
  - Awaiting Approval
    - Angiomax/Angiox
    - Hemopure
    - Mircera/C.E.R.A./R744
    - Epoch
    - Ferinject
    - Lovenox
    - Plavix
    - Soluble Ferric Pyrophosphate (SFP)
  - Phase Iii Clinical Trials
    - Amg-531
    - Apixaban
    - ATryn
    - Azd-6140
    - Beriplex P/N
    - Idraparinux Long-Acting Pentasaccharide
    - Cangrelor
    - Elaprin
    - Ferumoxytol
    - Hematide
    - Hemospan
    - Hemoxin/Nicosan/Niprisan
    - Ica-17043
    - Mozobil (AMD3100)
    - NovoSeven
    - Oxygent
    - PolyHeme
    - Procrit (Epoetin Alfa)
    - Promacta (Eltrombopag Olamine)
    - Refacto Af
    - Rendix (Dabigatran Etexilate)
    - Rivaroxaban (Bay 59-7939)
Chapter 5 - Industry Structure
- Competitive Analysis
  - Anemia Treatments
  - Hemophilia Treatments
  - Neutropenia Treatments
  - Thrombosis Treatments
- Industry Participants by Product Type
Chapter 6 - Patents
- Patent Analysis by Manufacturer
  - Patents by Application
    - Anemia Applications
    - Hemophilia
    - Neutropenia
    - Thrombosis
  - Leading Market Manufacturers
Chapter 7 - Company Profiles
- Amgen, Inc.
- Baxter Intl., Inc.
- Bayer Ag
- Biopure Corporation
- Bristol-Myers Squibb Co.
- Chugai Pharmaceutical Co., Ltd.
- Csl Behring
- Genzyme
- Tel: 617/252-7500
- Glaxosmithkline, Plc
- Icagen, Inc.
- Medicines Company (THE)
- Novo Nordisk A/S
- Ortho Biotech Products, Lp
- Roche
- Sanofi-Aventis
- Schering-Plough Corp.
- Wyeth
Chapter 8 - Appendices
- Company Contact Information
- Blood Disorder Associations and Resources Contact Information
List of Tables
- Table 1 Common Causes of Anemia
- Table 2 Types of Anemia
- Table 3 Common Causes of Hemophilia
- Table 4 Common Infectious Causes of Neutropenia
- Table 5 Common Medication Causes of Anemia
- Table 6 Common Causes of Thrombocytopenia
- Table 7 Common Causes of Thrombosis
- Table 8 U.S. Cases of Selected Chronic Conditions/ Diseases Treated with Blood Treatments, Estimated 2007
- Table 9 Worldwide Cases of Selected Chronic Conditions/Diseases Treated with Blood Treatments, Estimated 2007
- Table 10 U.S. Population by Selected Age Groups and by Percent of Total Population, through 2012 (MILLIONS)
- Table 11 Worldwide Population by Selected Age Groups and by Percent of Total Population, through 2012 (MILLIONS)
- Table 12 Marketed Biotechnology Blood Treatments
- Table 13 Marketed Biotechnology Product Impact
- Table 14 Key Anemia Treatments
- Table 15 Key Hemophilia Treatments
- Table 16 Key Neutropenia Treatments
- Table 17 Key Thrombosis Treatments
- Table 18 Newly Approved Blood Disorder Treatments
- Table 19 Global Market for Blood Disorder Treatments, through 2012 ($ Millions)
- Table 20 Geographical Distribution of Revenues in The Worldwide Blood Disorder Treatments Market, through 2012 ($ Millions)
- Table 21 Global Market for Anemia Treatments, through 2012 ($ Millions)
- Table 22 Geographical Distribution of Revenues in The Worldwide Anemia Treatments Market, through 2012 ($ Millions)
- Table 23 Global Market for Hemophilia Treatments, through 2012 ($ Millions)
- Table 24 Geographical Distribution of Revenues in The Worldwide Hemophilia Treatments Market, through 2012 ($ Millions)
- Table 25 Global Market for Neutropenia Treatments, through 2012 ($ Millions)
- Table 26 Geographical Distribution of Revenues in The Worldwide Neutropenia Treatments Market, through 2012 ($ Millions)
- Table 27 Global Market for Thrombosis Treatments, through 2012 ($ Millions)
- Table 28 Geographical Distribution of Revenues in The Worldwide Thrombosis Treatments Market, through 2012 ($ Millions)
- Table 29 Selected Blood Disorder Treatments in Development
- Table 30 Total Manufacturers' Market Shares of Blood Disorder Treatments, 2007
- Table 31 Total Manufacturers' Market Shares of Anemia Treatments, 2007
- Table 32 Total Manufacturers' Market Shares of Hemophilia Treatments, 2007
- Table 33 Total Manufacturers' Market Shares of Neutropenia Treatments, 2007
- Table 34 Total Manufacturers' Market Shares of Thrombosis Treatments, 2007
- Table 35 Blood Disorder Treatment Manufacturers by Product Type, 2007
- Table 36 Selected Manufacturer Patents for Blood Disorder and Related Technology by Application, 1976-Present
- Table 37 Patent Analysis by Selected Leading Blood Disorder Treatment Manufacturers, 1976-Present
- Table 38 List of Companies
List of Figures
- Figure 1 U.S. Cases of Selected Leading Chronic Conditions/Diseases Treated with Blood Treatments, Estimated 2007 (%)
- Figure 2 Worldwide Cases of Selected Leading Chronic Conditions/Diseases Treated with Blood Treatments, Estimated 2007 (%)
- Figure 3 U.S. Population by Selected Age Groups, 2005-2012 (MILLIONS)
- Figure 4 Worldwide Population by Selected Age Groups, 2005-2012 (MILLIONS)
- Figure 5 Percent of Recent Blood Disorder Approvals by Treatment Type (%)
- Figure 6 Global Market for Blood Disorder Treatments, 2005-2012 ($ Millions)
- Figure 7 Geographical Distribution of Revenues in The Worldwide Blood Disorder Treatments Market, 2005-2012 ($ Millions)
- Figure 8 Global Market for Anemia Treatments, 2005-2012 ($ Millions)
- Figure 9 Geographical Distribution of Revenues in The Worldwide Anemia Treatments Market, 2005-2012 ($ Millions)
- Figure 10 Global Market for Hemophilia Treatments, 2005-2012 ($ Millions)
- Figure 11 Geographical Distribution of Revenues in The Worldwide Hemophilia Treatments Market, 2005-2012 ($ Millions)
- Figure 12 Global Market for Neutropenia Treatments, 2005-2012 ($ Millions)
- Figure 13 Geographical Distribution of Revenues in The Worldwide Neutropenia Treatments Market, 2005-2012 ($ Millions)
- Figure 14 Global Market for Thrombosis Treatments, 2005-2012 ($ Millions)
- Figure 15 Geographical Distribution of Revenues in The Worldwide Thrombosis Treatments Market, 2005-2012 ($ Millions)
- Figure 17 Total Manufacturers' Market Shares of Blood Disorder Treatments, 2007
- Figure 18 Total Manufacturers' Market Shares of Anemia Treatments, 2007 (%)
- Figure 19 Total Manufacturers' Market Shares of Hemophilia Treatments, 2007 (%)
- Figure 20 Total Manufacturers' Market Shares of Neutropenia Treatments, 2007 (%)
- Figure 21 Total Manufacturers' Market Shares of Thrombosis Treatments, 2007
- Figure 22 Blood Disorder Treatment Markets-Number of Key Manufacturers by Product Type, 2007 (%)